23 results about "Inositol phosphate" patented technology

The present invention relates to chemical compounds useful as inhibitors of class II phosphoinositide 3-kinase (PI3K) signaling. The invention further relates to the medical use of inhibitors of class II phosphoinositide 3-kinase (PI3K) signaling in the treatment of medical conditions associated with defective and / or pathological class II phosphoinositide 3-kinase (PI3K) signaling, such as stroke, cardiovascular diseases associated with endothelial cell dysfunction, cancer, cancerometastasis, myopathy and diabetes.

The invention relates to the technical field of biomedicine detection, and discloses a tumor cell marker detection system for predicting the activation state of intracellular protein kinase. Comprising a marker detection module used for qualitatively detecting epithelial cell markers, mesenchymal cell markers, cell polarity markers and extracellular matrix related markers in tumor cells; the data processing module is used for performing cross validation on an epithelial cell marker, a mesenchymal cell marker, a cell polarity marker and an extracellular matrix related marker; the dynamic weighting module is used for performing dynamic weighting on different markers based on a complex system theory, and endowing epithelial cadherin with a higher weight; and the judgment module is used for determining whether epithelial intercellular substance transformation occurs or not according to the dynamically weighted marker data, and predicting the activation state of intracellular phosphoinositide 3-kinase alpha and the invasiveness of tumor cells based on the determination result of the epithelial intercellular substance transformation.

The present disclosure provides a soothing repair composition for dry sensitive skin and its preparation method and application, belonging to the technical field of cosmetics. The soothing repair composition of the present disclosure is a liposome structure. Cephalin and ceramide-EOP form a cephalin-ceramide complex, which serves as the shell layer of the liposome. The plant moulting hormone and glycerophosphoinositol choline salt are wrapped inside the liposome. The soothing repair composition with the liposome structure has excellent moisturizing, soothing and repairing effects.

This invention relates to the field of agricultural fertilizer technology, specifically to a phosphoinositol-chitosan composite organic fertilizer and its preparation method. The organic fertilizer comprises modified phosphoinositol, chitosan graft, humic acid, sugar alcohol chelated zinc, alginate oligosaccharide, bentonite, and a well-rotted organic carrier. Specifically, the modified phosphoinositol and chitosan graft synergistically form a "dual-signal driven" system, effectively activating signaling pathways related to plant root development; the alginate oligosaccharide and sugar alcohol chelated zinc synergistically enhance plant stress resistance; and humic acid and bentonite jointly improve soil structure and achieve slow nutrient release. This organic fertilizer integrates nutrient supply, soil improvement, and physiological regulation, significantly promoting crop root growth, enhancing its resistance to drought, low temperatures, and diseases, and achieving stable yield increases. Furthermore, the raw materials are natural and environmentally friendly, the process is simple, and it is suitable for large-scale production.

The application discloses a pesticide synergist and a preparation method thereof. The pesticide synergist comprises a silanol-initiated polyether shown in formula I, an inositol phosphate-initiated polyether shown in formula II, an alcohol auxiliary agent and water. The silanol-initiated polyether shown in formula I and the inositol phosphate-initiated polyether shown in formula II are synergized, so that the adhesion, spreading, penetration and retention capacity of pesticide droplets on a target surface are significantly enhanced, and the utilization rate of the pesticide is effectively improved. The product has the advantages of low toxicity, environmental friendliness, multi-functional synergism, wide compatibility and the like, the preparation process is simple and stable, and the product is suitable for industrial production.

The disclosure relates to adoptive cell therapy compositions including a population of isolated immune cells that are obtained from a donor subject. The immune cells can be modified to suppress Bruton's tyrosine kinase (BTK), interleukin-2-inducible T cell kinase (ITK), delta isoform of phosphoinositide 3-kinase (PI3Kδ), helios, blimp1, SOCS1, GATA3, IL-10, STAT3, TOX, CD25, foxp3, Ezh2, TGF-beta Receptor II, LAG-3, PD-1, TNF-alpha, or combinations thereof. The immune cells are optionally depleted of CD8+ T cells by about 10-fold or greater relative to un-depleted leukocytes.

Disclosed herein are methods of treating glioblastoma in a subject comprising, among others, administration of sub-maximal tolerance doses and / or intermittent doses of phosphoinositide 3-kinase (PI3K) inhibitors, autophagy inhibitors and / or checkpoint inhibitors.

The invention discloses a phosphoinositide 3-kinase allosteric inhibitor for treating diseases related to PI3K (phosphoinositide 3-kinase) regulation, and particularly provides a compound shown as a formula I or a pharmaceutically acceptable salt thereof. The phosphoinositide 3-kinase allosteric inhibitor can effectively inhibit PI3K alpha mutation, especially PI3K alpha H1047R mutation in an allosteric targeting mode, has good selectivity and is expected to treat and / or prevent related diseases or obstacles.

The invention refers to the field of neurodegenerative diseases including Alzheimer's Disease and a treatment thereof with a Benzoxazepine compound. Benzoxazepine compounds are e.g. known in the treatment of breast cancer and according to the use of the invention are a first therapeutic and prophylactic treatment for neurodegenerative diseases, including Alzheimer's Disease. The invention further relates to test systems for identifying, mapping, elaborating and evaluating said and further therapeutic and prophylactic uses of compounds of interest and / or other pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's Disease. (AD)

The invention discloses a low-conductivity cooling liquid and a preparation method thereof. The low-conductivity cooling liquid comprises an alcohol coolant, deionized water, a low-ionization-degree organic carboxylic acid corrosion inhibitor, an azole corrosion inhibitor, alkoxy alkyl silane, an inositol phosphate compound, a pH regulator and a defoaming agent. During preparation, all the components are sequentially stirred and added to obtain the low-conductivity cooling liquid. According to the low-conductivity cooling liquid disclosed by the invention, the low-ionization-degree organic carboxylic acid corrosion inhibitor, the azole corrosion inhibitor, the alkoxy alkyl silane and the inositol phosphate compound are compounded to form a specific system formula, and then the specific system formula is combined with the alcohol cooling agent and the water, so that the low-conductivity cooling liquid not only has strong corrosion resistance, but also has excellent system stability; the stability of the anti-freezing liquid during working or storage can be guaranteed, and the components are prevented from being decomposed and reacting to generate complexes or precipitates, so that the conductivity of the cooling liquid is stabilized.

Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and / or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.

Provided is a 3-phosphoinositide-dependent protein kinase 1 (PDK1) modulator compound. The PDK1 modulator compound is provided as a compound represented by chemical formula 1, or a solvate, hydrate, prodrug, stereoisomer or pharmaceutically acceptable salt thereof, and regulates, inhibits or antagonizes the activity of PDK1, and thus can be used for anticancer, antifibrosis, anti-aging and reverse aging, or treatment or prevention of Alzheimer's disease or autoimmune disease. In addition, the present invention provides a composition for anticancer, antifibrosis, anti-aging and reverse aging, or treatment, prevention or alleviation of Alzheimer's disease or autoimmune disease, containing the PDK1 modulator compound and a salt thereof as active ingredients, and provides a method, in which the compound and a salt thereof are administered to a subject, for anticancer, antifibrosis, anti-aging and reverse aging, or treatment, prevention or alleviation of Alzheimer's disease or autoimmune disease.

Aspects disclosed herein relate to compositions comprising novel phosphoinositide 3-kinase (PI3K) inhibitors, and methods of making the novel PI3K inhibitors. Further, various aspects relate to one or more methods of treating a disease using the compositions disclosed herein, including targeted delivery of the novel PI3K inhibitors disclosed herein.

The present disclosure relates to the use of phosphoinositide 3-kinase (PI3K) inhibitors targeting allosteric and normal pockets of PI3K in methods of treating, preventing, or ameliorating diseases or conditions in which PI3K functions (or in use in treating, preventing, or ameliorating diseases or conditions). The PI3K inhibitors can be used in combination and can target allosteric or normal pockets of PI3K alpha simultaneously, separately, or sequentially. In some aspects of the disclosed methods, PI3K [alpha] inhibitors may target an allosteric or normal pocket of a PI3K [alpha] mutant that is resistant to treatment with another PI3K [alpha] inhibitor that targets a different pocket of PI3K [alpha].

The invention discloses an anti-wrinkle repairing composition based on synergism of polypeptide and plant extract and application of the anti-wrinkle repairing composition, and belongs to the technical field of cosmetics. The composition is prepared from the following six active ingredients in percentage by weight: decapeptide-4, inositol choline glycerophosphate, betaine, medicinal rheum officinale root extract, Chinese herbaceous peony root extract and glycoprotein. And auxiliary materials acceptable in cosmetics. All the active ingredients have a synergistic effect in a specific concentration range to form a functional module for resisting aging, repairing, conditioning oil pox and strengthening a barrier. Preferably, the composition also comprises deionized water, glycerol, butanediol, a specific thickening agent, an emulsifier, a pH regulator, a preservative and other auxiliary materials. The composition disclosed by the invention can be used for integrally and efficiently improving various oil acne skin-sensitive problems such as wrinkles, coarse pores, excessive grease secretion, skin redness and fragile barriers, has the characteristics of synergistic interaction, mildness and safety, and can be applied to preparation of skin care products such as essence and face cream.

Provided is a 3-phosphoinositide-dependent protein kinase 1 (PDK1) modulator compound. The PDK1 modulator compound is provided as a compound represented by chemical formula 1, or a solvate, hydrate, prodrug, stereoisomer or pharmaceutically acceptable salt thereof, and regulates, inhibits or antagonizes the activity of PDK1, and thus can be used for anticancer, antifibrosis, anti-aging and reverse aging, or treatment or prevention of Alzheimer's disease or autoimmune disease. In addition, the present invention provides a composition for anticancer, antifibrosis, anti-aging and reverse aging, or treatment, prevention or alleviation of Alzheimer's disease or autoimmune disease, containing the PDK1 modulator compound and a salt thereof as active ingredients, and provides a method, in which the compound and a salt thereof are administered to a subject, for anticancer, antifibrosis, anti-aging and reverse aging, or treatment, prevention or alleviation of Alzheimer's disease or autoimmune disease.

Methods and compositions for treating, inhibiting, and / or preventing diseases or disorders associated with aberrant bromodomain-containing protein 4 (BRD4) and phosphoinositide 3-kinase (PBK) activity are disclosed, the methods comprise contacting a solution, cell, tissue, or subject expressing BRD4 and PBK with a compound having Benzopyran-4-One core.

Provided is a 3-phosphoinositide-dependent protein kinase 1 (PDK1) modulator compound. The PDK1 modulator compound is provided as a compound represented by chemical formula 1, or a solvate, hydrate, prodrug, stereoisomer or pharmaceutically acceptable salt thereof, and regulates, inhibits or antagonizes the activity of PDK1, and thus can be used for anticancer, antifibrosis, anti-aging and reverse aging, or treatment or prevention of Alzheimer's disease or autoimmune disease. In addition, the present invention provides a composition for anticancer, antifibrosis, anti-aging and reverse aging, or treatment, prevention or alleviation of Alzheimer's disease or autoimmune disease, containing the PDK1 modulator compound and a salt thereof as active ingredients, and provides a method, in which the compound and a salt thereof are administered to a subject, for anticancer, antifibrosis, anti-aging and reverse aging, or treatment, prevention or alleviation of Alzheimer's disease or autoimmune disease.

The invention provides a composition with an instant red fading effect and application of the composition. The composition comprises a pinus densiflora extract, a radix gentianae extract and inositol choline glycerophosphate. The Pinus densiflora extract, the Gentiana scabra Bunge extract and the glycerophosphoinositide choline salt have a synergistic effect, and are combined for compatibility to inhibit release of inflammatory factors, so that vasodilatation and redness signals caused by inflammation are blocked from the source, and the skin barrier is immediately faded, relieved and repaired.

Provided is a 3-phosphoinositide-dependent protein kinase 1 (PDK1) modulator compound. The PDK1 modulator compound is provided as a compound represented by chemical formula 1, or a solvate, hydrate, prodrug, stereoisomer or pharmaceutically acceptable salt thereof, and regulates, inhibits or antagonizes the activity of PDK1, and thus can be used for anticancer, antifibrosis, anti-aging and reverse aging, or treatment or prevention of Alzheimer's disease or autoimmune disease. In addition, the present invention provides a composition for anticancer, antifibrosis, anti-aging and reverse aging, or treatment, prevention or alleviation of Alzheimer's disease or autoimmune disease, containing the PDK1 modulator compound and a salt thereof as active ingredients, and provides a method, in which the compound and a salt thereof are administered to a subject, for anticancer, antifibrosis, anti-aging and reverse aging, or treatment, prevention or alleviation of Alzheimer's disease or autoimmune disease.

The invention provides a characteristic phospholipid molecular biomarker in plasma, a screening method thereof and application of the characteristic phospholipid molecular biomarker in preparation of a kit for diagnosing pneumoconiosis. The characteristic phospholipid molecules at least comprise the following nine phospholipid molecules: lysophosphatidylcholine (12: 0), phosphatidylcholine (16: 0 / 16: 0), phosphatidylcholine (18: 0 / 18: 1), phosphoinositide (16: 0 / 18: 1), lysophosphatidic acid (16: 0), phosphatidyl glycerol (16: 0 / 16: 0), phosphatidylserine (18: 1 / 18: 1), phosphatidylcholine (18: 0 / 20: 2) and lysophosphatidyl ethanolamine (18: 2). The TC value is calculated by calculating the quantitative values of the nine characteristic phospholipid molecules and a classification model constructed based on a support vector machine algorithm, the risk of pneumoconiosis is predicted according to the TC value, pneumoconiosis patients and non-pneumoconiosis patient groups can be accurately distinguished, and the method is used for pneumoconiosis diagnosis and early screening.

The application discloses a kind of detection methods of inositol hexakisphosphate and its application in plant cultivation, the application utilizes the electrostatic and chelation of nano iron oxide and inositol hexakisphosphate Induce nanoparticle aggregation, cause color change or UV-Vis absorption peak shift (200~220 nm), for the rapid detection of inositol hexakisphosphate concentration in soil or nutrient solution, detection limit 0.1 mg / L, total time <10 minutes.The method includes sample extraction, reaction and optical determination steps, suitable for on-site monitoring of phosphorus fixation and fertilizer quality control.The detection results of the application can guide the application of complex, improve the phosphorus utilization efficiency by 20~30%, and enhance the plant cultivation effect (such as alfalfa yield increase by 18%, rice growth period is shortened by about 7 days).The method of the application is suitable for soil phosphorus fixation monitoring.